Department of Critical Care, University Medical Center Groningen, Groningen, 9713 GZ, the Netherlands.
Department of Epidemiology, University Medical Center Groningen, Groningen, 9713 GZ, the Netherlands.
Syst Rev. 2023 Dec 13;12(1):233. doi: 10.1186/s13643-023-02401-3.
Patients in the intensive care unit (ICU) are highly heterogeneous in characteristics, their clinical course, and outcomes. Genetic variability may partly explain the variability and similarity in disease courses observed among critically ill patients and may identify clusters of subgroups. The aim of this study is to conduct a systematic review of all genetic association studies of critically ill patients with their outcomes.
This systematic review will be conducted and reported according to the HuGE Review Handbook V1.0. We will search PubMed, Embase, and the Cochrane Library for relevant studies. All types of genetic association studies that included acutely admitted medical and surgical adult ICU patients will be considered for this review. All studies will be selected according to predefined selection criteria, evaluated and assessed for risk of bias independently by two reviewers. Risk of bias will be assessed according to the HuGE Review Handbook V1.0 with some modifications reflecting recent insights. We will provide an overview of all included studies by reporting the characteristics of the study designs, the patients included in the studies, the genetic variables, and the outcomes evaluated.
We will use data from peer-reviewed published articles, and hence, there is no requirement for ethics approval. The results of this systematic review will be disseminated through publication in a peer-reviewed scientific journal.
PROSPERO CRD42021209744.
重症监护病房(ICU)的患者在特征、临床过程和结局方面存在高度异质性。遗传变异性可能部分解释了重症患者疾病过程中观察到的可变性和相似性,并可能确定亚组聚类。本研究旨在对所有与危重症患者结局相关的遗传关联研究进行系统评价。
本系统评价将按照 HuGE 审查手册 V1.0 进行和报告。我们将搜索 PubMed、Embase 和 Cochrane 图书馆以获取相关研究。所有类型的遗传关联研究,包括急性入住的内科和外科成人 ICU 患者,都将被纳入本综述考虑。所有研究将根据预先设定的选择标准进行选择,由两名评审员独立评估和评估偏倚风险。根据 HuGE 审查手册 V1.0 进行偏倚风险评估,并根据最近的研究结果进行一些修改。我们将通过报告研究设计的特征、研究中纳入的患者、遗传变量和评估的结局,对所有纳入的研究进行概述。
我们将使用同行评审发表文章的数据,因此不需要伦理批准。本系统评价的结果将通过在同行评审的科学期刊上发表来传播。
PROSPERO CRD42021209744。